November 6, 2020

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A randomized, open-label, phase 3 trial of remdesivir in hospitalized patients who did not require mechanical ventilation showed that there was no significant difference between a 5-day versus a 10-day course of treatment on the outcome of clinical status on a 7-point scale at day 14 in patients with confirmed SARS-CoV-2 infection. The authors note that there was no placebo control group in this study, and therefore the magnitude of benefit cannot be determined.

Goldman et al. (Nov 5, 2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2015301